Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, 2026, highlighted by a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential increase from Q4 2025. The company attributed the growth to both new account activations and deeper utilization within existing sites, signaling increasing integration of Nociscan into clinical workflows for chronic low back pain.
The commercial-stage healthcare technology company leverages its Nociscan platform, which uses biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of discogenic pain. With approximately 5.8 million lumbar MRIs performed annually in the U.S. for low back pain, Aclarion sees a potential $2 billion market opportunity for technologies like Nociscan that provide objective, data-driven evaluation.
Reimbursement progress has been a key catalyst. Nociscan has been reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K.—for several months. This early payer adoption provides a pathway for broader coverage expansion. In the U.S., the company continues to engage with payers through its Nociscan Reimbursement Program.
Aclarion also advanced its clinical pipeline. The CLARITY randomized trial, designed to validate the clinical utility of Nociscan in guiding treatment decisions, is progressing. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions.
On the intellectual property front, Aclarion strengthened its portfolio with a new patent covering the use of AI in workflows of future products. The company now holds 64 issued and pending patents worldwide, reinforcing its competitive moat.
Financially, Aclarion reported a strong balance sheet with $19.0 million in cash, no debt, and a clean capital structure as of March 31, 2026. The company also announced a $2.5 million share repurchase program. Based on current operating plans, management believes existing cash resources are sufficient to fund operations into the second half of 2027.
"Q1 represents a clear inflection for Aclarion," said Brent Ness, CEO of Aclarion, in a statement. "Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US." He emphasized that the company is still in the early stages of commercializing Nociscan into a large and underpenetrated market.
The company also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. The video is available here.
With 2,444,871 common shares outstanding as of March 31, 2026, and 2,882,371 on a fully diluted basis, the company has approximately $6.60 per share in cash. For more information, visit www.aclarion.com.
